DELIVERY OF GENES TO BLOCK HTLV-III EXPRESSION

传递基因以阻断 HTLV-III 表达

• 批准号: 3488529
• 负责人: RICHARD D MACDONALD
• 金额: $ 5万
• 依托单位: SYNTRO CORPORATION
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-07-01 至 1986-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3488529
• 关键词: AIDS; Betaherpesvirinae; antiAIDS agent; antiviral agents; attenuated microorganism; biotechnology; drug delivery systems; gene expression; gene therapy; genetic manipulation; genetic recombination; genetic translation; helper T lymphocyte; human immunodeficiency virus 1; molecular cloning; nucleic acid chemical synthesis; synthetic nucleic acid; synthetic vaccines; tissue /cell culture; transposon /insertion element; viral vaccines; virus DNA; virus RNA; virus antigen; virus genetics; virus replication

Human T-cell lymphotropic virus-III (HTLV-III) is almost certainly the causal agent of the epidermic human disease Acquired Immunodeficiency Syndrome (AIDS). AIDS is a major health problem in the U.S. and an effective means of preventing the spread of the disease would be of great value. This proposal focuses on interrupting the cycle of viral replication and expression of viral antigens in individuals exposed to or already infected with the virus. Syntro Corporation, using recombinant DNA technology, has developed proprietary methods for the delivery to and expression of gnes in animals to produce effective vaccines. In Phase I of the proposal, this technology will be applied to construct genes which, upon expression, should block the replication of HTLV-III in T-cel lymphocytes. In Phase II, these constructs will be placed in the appropriate delivery system and tested for efficacy.

人类 T 细胞嗜淋巴细胞病毒-III (HTLV-III) 几乎 肯定是人类表皮疾病的致病因素 获得性免疫缺陷综合症（艾滋病）。 艾滋病是一个重大 美国的健康问题及预防的有效方法 这种疾病的传播将具有巨大的价值。 该提案的重点是中断病毒的循环 病毒抗原在个体中的复制和表达 暴露于或已经感染病毒。 Syntro 公司利用重组 DNA 技术， 开发了专有的方法来交付和 在动物中表达基因以生产有效的疫苗。 在该提案的第一阶段，该技术将应用于 构建基因，该基因在表达后应阻断 HTLV-III 在 T 细胞淋巴细胞中的复制。 在第二阶段， 这些构建体将被放置在适当的交付中 系统并测试其功效。